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AA Amino acid 
CEL/CEL Carboxyl ester lipase protein/gene 
CELP Carboxyl ester lipase pseudogene  
dH2O  Distilled water 
DNA Deoxyribonucleic acid  
EDTA Ethylenediaminetetraacetic acid 
EV Empty vector 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
ICC Immunocytochemistry 
HEK293 Human embryonic kidney cell line 293 
IHC Immunohistochemistry 
INS Insertion of a cytosine in the CEL VNTR region 
INS9 Insertion in the 9th repeat of the VNTR in the CEL gene 
INS11 Insertion in the 11th repeat of the VNTR in the CEL gene 
kDa Kilo Daltons 
mL Milliliter 
o/n Overnight 
PCR Polymerase chain reaction 
PDAC Pancreatic ductal adenocarcinoma 
PP Pancreatic polypeptide 
RT Room temperature 
Rpm Revolutions per minute 
VIP Vasoactive intestinal peptide 
TRUNC Truncated artificial variant of the CEL gene (lacking all of the VNTR region) 








Carboxyl ester lipase (CEL) is a digestive enzyme that is mainly expressed in the acinar cells 
of the pancreas. The CEL gene is highly polymorphic due to a variable number of tandem 
repeat (VNTR) region in the last exon. Diseases that are associated with CEL are related to 
alterations in the VNTR region. Single base insertions in the VNTR cause a premature stop 
codon and a truncated protein. It is not clear whether these insertions are linked to pancreatic 
disease.  
In this study, we wanted to investigate the location of the insertions and the frequency by 
sequencing human DNA samples. We further aimed to test tail-specific antibodies for the 
normal CEL protein (CEL-WT) and the CEL insertion variants (CEL-INS9 and CEL-INS11) 
by western blot, immunocytochemistry and immunohistochemistry. Moreover, we wanted to 
study the impact of CEL insertion variants in a cellular model system, thereby evaluating if 
insertions in the CEL VNTR potentially could be pathogenic.  
We sequenced 50 human DNA samples from the Pancreas Biobank at Gade Laboratory for 
Pathology, Department of Clinical Medicine, University of Bergen. We noticed five cases 
with INS9, one case with INS10 and one case with INS12, which results in a carrier 
frequency of 14 %.  However, we observed that the five cases with insertion in repeat 9 all 
had a VNTR length of 13 on one of the alleles. We further investigated this by sequencing all 
remaining DNA samples in the Pancreas Biobank with a 13 repeat VNTR length (N=25) and 
observed that in total, 23 of 31 samples had insertion in repeat 9 and a VNTR length of 13 on 
one of the alleles. 
The CEL-WT protein has a C-terminal that ends with the six amino acids, PAVIRF. However, 
if an insertion occurs in the CEL VNTR it results in a truncated protein and a C-terminal that 
ends with the sequence PRAAHG. Tail-specific antibodies have been produced towards these 
C-terminal ends. We tested the tail-specific antibodies by western blotting, 
immunocytochemistry and immunohistochemistry. The tail-specific antibodies were highly 
specific in the western blots, but did not display the same specificity by 
immunocytochemistry and immunohistochemistry.  
Finally, we studied the effect of insertions in the CEL VNTR on protein secretion and 
aggregation in HEK293 cells. We observed that the insertion variants were similarly detected 
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in the lysate and the medium. However, we detected more of the CEL-INS9 variant, than 
CEL-INS11 and CEL-WT in the pellet fraction.  
In summary, we have shown that there is an association between insertion in repeat 9 of the 
CEL VNTR and a VNTR length of 13. We also found that the tail-specific antibodies had the 
highest specificity in western blot analysis. Moreover, our data indicated that insertions may 
affect the distribution of the CEL protein in different cellular fractions, thereby implicating 
















1. Introduction  
1.1 The pancreas and its diseases  
The pancreas is located in the upper part of the abdominal cavity (Fig. 1.1 A), has an 
elongated structure and is approximately 15-20 cm long (Holck, 2017). Ligaments and vessels 
demarcate the organ into a head, body and tail region (Kumar et al., 2013).The pancreas 
consists of an endocrine and an exocrine part. The endocrine part represents 1-2 % of the total 
volume and produces hormones, which are secreted into the blood stream. The exocrine part, 
which constitutes the major volume of the organ, excretes digestive enzymes to the duodenum 
(Fig.1.1B) (Kumar et al., 2013).  
 
 
Figure 1.1 Location and characteristics of the human pancreas. A) The pancreas is located in the upper part of the 
abdominal cavity, behind the stomach. Figure adapted from: https://www.pancan.org/facing-pancreatic-cancer/about-
pancreatic-cancer/what-is-the-pancreas/ B) The endocrine pancreas constitutes 1-2 % of the organ and consists of cell clusters 
called Islet of Langerhans that secrete hormones to the bloodstream.  The exocrine pancreas constitutes the major volume of 
the pancreas and consists of acinar cells arranged in acini and duct cells that excrete digestive enzymes and NaHCO3 to the 
duodenum, respectively. Figure adapted from: https://beyondthedish.wordpress.com/tag/pancreatic-ducts/ 
 
1.1.1 The exocrine pancreas  
The exocrine pancreas consists of acini and the ductal system (Fig. 1.1B). The Acini have an 
irregular shape and contain acinar cells. The acinar cells synthesize, store and secrete 
digestive enzymes (Pandol, 2011). The acinar cell has two plasma membrane domains, the 
basolateral membrane and the apical membrane (Fig.1.2B) (Leung and Ip, 2006). The 
basolateral membrane is located towards the basal lamina (Fig. 1.2A) and contains receptors 
for neurotransmitters and hormones which stimulate the secretion of digestive enzymes. The 
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apical membrane is faced towards the acinar lumen and is connected to a tiny duct  (Leung 
and Ip, 2006). The basal and the apical regions of the cell have different roles; the basal part 
contains the nucleus and endoplasmic reticulum for protein synthesis while the apical part 
store digestive enzymes in zymogen granules (Fig. 1.2B) (Pandol, 2011). The digestive 
enzymes are secreted into the lumen of the acinus which is connected to a ductal system 
(Pandol, 2011). Acinar cells are connected via the so-called centroacinar cells to ductal cells, 






 into the ducts (Fig.1.2A) (Junqueira and 
Carneiro, 2003, VanPutte et al., 2014). The exocrine secretions of the pancreas, which 







produced in the ductal cells, makes up the pancreatic juice (VanPutte et al., 2014).  
 
Figure 1.2 Structure of an acinus and an acinar cell. A) Schematic overview of the acinus in connection with the ductal 
system. Figure adapted from:  https://www.diapedia.org/other-types-of-diabetes-mellitus/4104085136/acute-pancreatitis B) 
In the acinar cells, the digestive enzymes are stored in zymogen granules and released into the ducts when the pancreas is 
stimulated to secrete. The acinar cell has two plasma membrane domains, the apical- and basal membranes, respectively. 
Figure adapted from; (Burgoyne and Morgan, 2003). 
The acinar cells secrete three main types of enzymes into the small intestine; proteases, 
amylases and lipases for the digestion of proteins, carbohydrates and fat, respectively (Holck, 
2017). The proteases are generally made as inactive pro-enzymes to prevent self-digestion of 
the organ and are stored together with amylases and lipases in the zymogen granules of the 
acinar cells (Kumar et al., 2013). Deoxy-ribonucleases and ribonucleases degrade DNA and 




Before the chyme (partially digested food) enters the duodenum, there is a slight increase in 
pancreatic secretion, due to an increased activity of the vagus nerve. The vagus nerve 
activates the secretion of gastrin, which is a hormone that is produced in the stomach. Further, 
gastrin stimulates the secretion of pepsin and hydrochloric acid (in the stomach). The major 
secretion of pancreatic juice, however, starts when the chyme enters the duodenum (Sand et 
al., 2011, Øyri, 2011). Two hormones that stimulate the exocrine pancreas are secreted from 
the duodenal epithelium: cholecystokinin and secretin. Cholecystokinin promotes secretion of 
the enzyme-rich fluid secreted by zymogen granules. Secretin stimulates the secretion of 
bicarbonate from the duct cells (Junqueira and Carneiro, 2003). The secretion of bicarbonate 
neutralizes the acidic stomach contents, giving the pancreatic enzymes an optimal pH for 
activity (Junqueira and Carneiro, 2003).  
1.1.2 Diseases of the exocrine pancreas  
Acute pancreatitis  
Acute pancreatitis is an acute inflammatory disorder of the pancreas (Kumar et al., 2013). In 
the start of the disease, swelling and fluid retention in the organ is observed, which can further 
develop into necrosis and bleeding (Aabakken, 2016). During disease progression there is 
insufficient secretion of pancreatic juice to the intestine, which may result in a high volume of 
digestive enzymes in the pancreas. Consequently, this could lead to pre-activation of digestive 
enzymes in the pancreas and thus lead to self-digestion and inflammation (Aabakken, 
2016).The main clinical feature of acute pancreatitis is abdominal pain, which can vary from 
mild to severe. The diagnosis is determined by exclusion of other causes of abdominal pain 
and elevated levels of lipase and amylase in blood plasma. The majority of acute pancreatitis 
cases are mild and reversible. However, 20 % of the cases of acute pancreatitis develop to 
severe diseases and may even be fatal (Kumar et al., 2013). 
Chronic pancreatitis 
Chronic pancreatitis is an long-standing inflammatory disease that results in an irreversible 
loss of pancreatic functions (Kumar et al., 2013, Kleeff et al., 2017). Long-term alcohol abuse 
and smoking are the main causes, but genetics also play a role in the pathogenesis (Kumar et 
al., 2013, Kleeff et al., 2017). The reason why alcohol causes chronic pancreatitis is not fully 
understood, but increased oxidative stress and direct injury to the acinar cells by inhibition of 
the endoplasmic reticulum (ER) activity may play a role (Kleeff et al., 2017). Chronic 
pancreatitis results in pain, progressive scarring of the pancreatic tissue and endocrine and 
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exocrine insufficiency due to loss of function of the parenchyma. The disease is associated 
with increased risk of developing pancreatic cancer. Recurrent attacks of acute pancreatitis 
may be the first stage in developing the disease. In the later stages, symptoms such as pain, 
steatorrhea and diabetes can be observed (Kleeff et al., 2017).  
Hereditary pancreatitis  
A rare cause of chronic pancreatitis is hereditary pancreatitis. This version of the disease is 
mainly due to germline mutations in the protease serine 1 gene (PRSS1). The penetrance of 
the disease is 80% and the inheritance pattern is autosomal dominant (Rebours et al., 2012). 
PRSS1 encodes the enzyme cationic trypsinogen, expressed in the acinar cells of the pancreas. 
Trypsinogen is a precursor of trypsin 1. PRSS1 mutations reduce the enzymatic activity or 
increase autocatalytic conversion of inactive trypsinogen to active trypsin 1 (Kleeff et al., 
2017). Reduced inactivation of trypsin 1 and premature conversion of trypsinogen to trypsin 
are believed to cause pancreatic injury through autodigestion of pancreatic tissue, leading to 
an inflammatory response and recurrent acute pancreatitis which then progresses towards 
chronic pancreatitis (Kleeff et al., 2017).  
Pancreatic cancer 
The most common type of pancreas cancer is the ductal adenocarcinoma (PDAC), i.e. a 
malignant tumor with ductal differentiation originating from glandular tissue (Bertelsen, 
2014, Hofsli, 2018). The first symptoms are vague, which often leads to a delayed diagnosis 
(Kumar et al., 2013). In the United States, pancreatic cancer has a 5 year survival of 
approximately 8% and is the third most common cause of cancer death (Tamura et al., 2018). 
The cause of the disease is not clearly understood, but pancreatitis, smoking and diet can 
contribute (Bertelsen, 2014). Inherited and acquired mutations in cancer-associated genes can 
also be a cause of pancreas cancer (Kumar et al., 2013).  
In pancreatic ductal adenocarcinoma, DNA abnormalities are most frequently found in one 
oncogene and three tumor suppressor genes. Ninety % of the tumors contain somatic 
mutations in the KRAS proto-oncogene (KRAS). The most frequently altered tumor 
suppressor gene is cyclin dependent kinase inhibitor 2A (CDKN2A), which encodes an 
essential cell cycle regulator. This gene has a loss of function in more than 90 % of ductal 
adenocarcinomas. Tumor protein 53 (TP53) is also a tumor suppressor gene, and somatic 
mutations in this gene are common in pancreatic cancer. TP53 encodes for a protein that is 
active in cellular stress response. Finally, SMAD family member 4 (SMAD4) is a tumor 
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suppressor gene that mediates signaling downstream of the transforming growth factor 
receptor (TGFβ). SMAD4 is inactivated in approximately 50 % of tumors (Kamisawa et al., 
2016). The cause of the molecular changes in the genes mentioned above is not known 
(Kumar et al., 2013). 
Adenocarcinoma of the pancreas mostly affects the elderly, and the majority of the patients 
are between the ages of 60 to 80 (Kumar et al., 2013, Bertelsen, 2014). When a tumor is 
located in the pancreatic head region, there might be an obstruction of the distal common bile 
duct. In 50 % of pancreatic cancer cases there is a distention of the biliary tract, which may 
lead to jaundice (Kumar et al., 2013).Weight loss and abdominal pain are other symptoms 
seen in the late stages of the disease (Bertelsen, 2014).   
1.1.3 The endocrine pancreas 
The endocrine pancreas represents 1-2 % of the volume of the organ and consists of four 
major cell types; alpha-, beta-, delta- and pancreatic polypeptide (PP) cells (Fig.1.3). These 
cells are arranged in clusters called the Islets of Langerhans (Kumar et al., 2013). The mean 
diameter of an adult human islet is 140 μm (In'T Veld and Marichal, 2010). The different cell 
types of the endocrine pancreas all produce and secrete hormones that regulate the glucose 
level in the blood stream. 
  
Figure 1.3 Features of the endocrine pancreas. The endocrine pancreas consists of four major cell types; beta, alpha, delta 






The beta cells produce insulin, while the alpha cells produce glucagon. A high level of 
glucose in the bloodstream promotes insulin secretion from the beta cells. The secretion of 
insulin will increase the uptake of glucose in the tissues and promote the production of 
glucose to glycogen in the liver. In contrast, a low level of glucose in the bloodstream will 
initiate the breakdown of glycogen, and thus increase the glucose level in the bloodstream 
(Holck, 2017).  
The release of both insulin and glucagon are suppressed by the hormone somatostatin that is 
produced in the delta cells (Kumar et al., 2013). The PP cells contain a pancreatic polypeptide 
called vasoactive intestinal peptide (VIP). VIP have several gastrointestinal effects, such as 
inhibition of intestinal motility and secretion and stimulation of gastric and intestinal enzymes 
(Kumar et al., 2013). 
1.1.4 Diseases of the endocrine pancreas 
Diabetes mellitus 
Diabetes mellitus is a common term for metabolic diseases that are characterized by chronic 
hyperglycemia (Kumar et al., 2013, Kharroubi and Darwish, 2015). Hyperglycemia is a result of 
insufficient insulin action, secretion, or both. The symptoms of the disease vary due to the 
duration and type of diabetes (Kharroubi and Darwish, 2015). The disease can be divided into two 
major groups; type 1 diabetes (T1D) and type 2 diabetes (T2D) (Kumar et al., 2013).  
T1D was formerly called “juvenile onset diabetes” or “insulin-dependent diabetes”. This form 
represents 5-10 % of diabetes cases and is most common in children and adolescents. The 
disease is caused by destruction of the pancreatic β-cells due to an autoimmune response, 
which results in an absence of insulin secretion (Kharroubi and Darwish, 2015, American 
Diabetes Association, 2017). A hallmark of T1D is the presence of one or more autoimmune 
markers like autoantibodies towards glutamate decarboxylase (GAD), the tyrosine 
phosphatases IA-1, IA-2B and ZnT8, and insulin. Both environmental factors and genetics 
have a central role in the development of the disease. The treatment for patients with type 1 
diabetes is insulin injections (Kharroubi and Darwish, 2015).  
T2D represents 90-95 % of all diabetes cases. The disease was previously called “adult onset 
diabetes” or “noninsulin dependent diabetes”. Individuals with T2D exhibit a peripheral 
insulin resistance and relative insulin deficiency (American Diabetes Association, 2017). This 
form of the disease does not include autoimmune β-cell destruction. The risk for developing 
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the T2D increases with body weight, age and lack of physical activity, and patients diagnosed 
with the disease are often obese. The patients develop hyperglycemia gradually but the 
symptoms may be silent enough for the disease to be undiagnosed for years. Weight reduction 
and/or pharmacological treatment may improve insulin resistance (American Diabetes 
Association, 2017). In the final phase of the disease, insulin injections may be necessary 
(Kharroubi and Darwish, 2015). 
Monogenic diabetes 
In addition to T1D and T2D, there are two other main categories of diabetes; gestational 
diabetes and “other specific types of diabetes” (American Diabetes Association, 2017). The 
latter includes monogenic diabetes, a group of diseases that affects the normal β-cell 
physiology or pancreas development (Molven and Njølstad, 2011). The disease is caused by a 
defect in a single gene, and mutations in around 20 genes are known to cause monogenic 
diabetes (Molven and Njølstad, 2011, Søvik et al., 2013). Neonatal diabetes and maturity-
onset diabetes of the young (MODY) are the two main types of monogenic diabetes (Søvik et 
al., 2013). 
 
1.2 Carboxyl ester lipase (CEL) 
Carboxyl ester lipase (CEL) is one of four major lipases that are secreted by the exocrine 
pancreas (Johansson et al., 2018). The digestive enzyme is also referred to as bile salt-
stimulated lipase (BSSL) (Hernell and Olivecrona, 1974) or bile salt-dependent lipase 
(BSDL) (Abouakil and Lombardo, 1989).  
1.2.1 The CEL protein 
CEL is mainly expressed in the acinar cells of the pancreas. The enzyme activity is stimulated 
by bile salts (hence its names BSSL/BSDL) and hydrolyzes cholesterol esters, dietary fat and 
fat-soluble vitamins (Lombardo et al., 1978, Lombardo and Guy, 1980, Bläckberg and 
Hernell, 1983, Hui and Howles, 2002). Of the total amount of detected proteins in pancreatic 
juice, CEL represents 4 % (Lombardo et al., 1978). CEL is also expressed in lactating 
mammary glands and secreted with the mother`s milk (Bläckberg et al., 1981). 
The CEL protein contains two major structural domains: a globular N-terminal domain with a 
signal peptide and a catalytic site, and a C-terminal including a variable number of tandem 
repeat (VNTR) domain (Fig. 1.4) (Reue et al., 1991, Terzyan et al., 2000). Each VNTR repeat 
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consists of 11 amino acids (AA) and the number of repeats vary from 3-23, with 16 as the 
most common. In addition, the VNTR is enriched in the amino acids proline (P), glutamine 
(E), serine (S), and threonine (T) (PEST sequences). The C-terminal is tailed by the unique 
sequence KEAQMPAVIRF (Johansson et al., 2018). Altogether, CEL give rise to a protein of 




Figure 1.4 Structure of the carboxyl ester lipase protein. CEL has a theoretical size of 79 kDa. The protein contains two 
major structural domains; a globular N-terminal with a catalytic site and a signal peptide, and a C-terminal with a VNTR 
region (here illustrated with 16 repeats). CEL is N-glycosylated at Asn187 and phosphorylated at Thr340. The VNTR region 
contains O-glycosylation sites which masks the PEST sequence.  
During the translation process of CEL, the polypeptide chain is released into the lumen of 
endoplasmic reticulum (ER) where it forms a folding complex with several chaperons after 
the cleavage of the N-terminal hydrophobic signal peptide (Lombardo, 2001, Johansson et al., 
2018). The protein is N-glycosylated in the ER, at residue Asn187 (Fig. 1.4). This 
modification is important for secretion and correct folding of CEL (Abouakil et al., 1993). 
The polypeptide is thereby transported to the Golgi apparatus, where the C-terminus is 
heavily O-glycosylated at serine and threonine residues in the PEST sequence (Bruneau et al., 
1997). It has been reported that PEST can be a signal for rapid protein degradation (Rogers et 
al., 1986). Thus, O-glycosylation of CEL could play a protective role by masking these PEST 
sequences (Loomes et al., 1999). 
CEL is phosphorylated at residue Thr340, after it has been completely glycosylated in the 
Golgi apparatus (Fig. 1.4). Phosphorylation of Thr340 allows final translocation through the 
secretory pathway (Pasqualini et al., 2000). The protein is then stored with other digestive 
enzymes in zymogen granules (Johansson et al., 2018). Some CEL molecules remain in 
complex with the molecular chaperone glucose-regulated protein with a size of 94 kDa 
(GRP94) when secreted into the duodenum (Bruneau et al., 1998). By renal filtration, the 
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protein is cleared from circulation, and can be detected in the urine of healthy individuals 
(Comte et al., 2006). 
1.2.2 The CEL gene 
The human CEL gene consists of 11 exons, covers approximately 10 kilobase pairs (kbp) of 
genomic sequence and is located on chromosome band 9q34.3 (Fig. 1.5) (Taylor et al., 1991, 
Lidberg et al., 1992). The VNTR is found in the last exon of the CEL gene, and this region 
consists of almost identical 33 base-pair (bp) segments each encoding the 11 AA repeats 
(Johansson et al., 2018). Located 11 kbp downstream and in tandem with CEL is the CEL-like 
pseudogene CELP (Lidberg et al., 1992, Madeyski et al., 1998).  CELP lacks exons 2-7 of 
CEL, and is not expected to translate into a functional protein (Nilsson et al., 1993). The 
promotor region of the mouse CEL gene is more similar to the promotor region of the CEL 
pseudogene than to CEL. Thus, it have been suggested that CELP is the original gene 
(Madeyski et al., 1998). 
 
Figure 1.5 Structure of the human carboxyl ester lipase locus. The human CEL locus is located on chromosome 9q34.3. 
The CEL gene (blue) consists of 11 exons and covers 10 kbp. CELP is a CEL-like pseudogene that that lacks exons 2-7 and is 
located 11 kbp downstream and in tandem, with CEL. 
1.2.3 Variants of the CEL gene 
Due to the VNTR region, the CEL gene is highly polymorphic (Torsvik et al., 2010, 
Johansson et al., 2018). In addition to VNTR-length variation, single nucleotide 
polymorphisms (SNPs), single base insertions and single base deletions have been reported. 
Furthermore, copy number variants (CNVs) of the CEL locus have been described (Johansson 
et al., 2018).  
VNTR length variants  
As mentioned above, the number of repeats in the VNTR region in human CEL vary between 
3-23, but 16 repeats are the most common (Johansson et al., 2018). The repeats differs also 
between species with examples like: no repeats in chicken, 3-4 repeats in rodents, 13 in dog 




The SNP denoted rs488087 causes a change from C to T in the second VNTR repeat. This SNP 
have been proposed to result in an increased risk of developing pancreatic cancer (Martinez et al., 
2015). However, only 30 patients with PDAC were included in this study. Thus, to conclude that 
this SNP gives an increased risk for PDAC, a significantly larger patient cohort has to be 
analyzed. 
INS  
Single base insertions in the VNTR region result in premature stop-codons and truncated CEL 
proteins. These mutations have been associated with fecal elastase deficiency in diabetic 
patients (Ræder et al., 2006). Insertions in repeat 4, 7, 8, 9, 10 and 11 have been observed 
(Johansson et al., 2018).The combined allele frequency of single base insertions is ca. 0.07 in 
normal controls of Northern European descent. Thus, the elimination of the C-terminal amino 
acid sequence KEAQMPAVIRF do not seem to have a high biological impact (Ræder et al., 
2006). 
The insertion of an extra cytosine in the CEL VNTR will give rise to a new C-terminal amino-
acid sequence; PRAAHG (normally: PAVIRF) (Fig. 1.6). Such insertions have been studied 
by Martinez et al. in pancreatic tissue specimens and in HEK293 cells (Martinez et al., 2016). 
They developed an antibody directed towards the new C-terminal PRAAHG sequence to be 
able to detect CEL insertion variants. Further, they suggested that CEL insertions may arise as 
early somatic mutations in PDAC and that the detection of the modified C-terminal could be 




Figure 1.6 Structure of CEL insertion variants. Insertion of a cytosine in the VNTR will lead to a premature stop-codon 
and a truncated protein, and the C-terminal will end with the six amino acids, PRAAHG. In this figure, the insertion variants 




Single base deletions in the VNTR result in a frameshift, premature stop codons and a 
truncated C-terminal. Two deletion variants of CEL have been observed with a deletion in the 
first (DEL1) and fourth (DEL4) repeat, respectively. DEL1 is predicted to change 110 amino 
acids in the C-terminal, while DEL4 is predicted to change 99 amino acids in the C-terminal 
(Johansson et al., 2018). CEL-DEL1 and CEL-DEL4 are causative mutations for the CEL-
MODY syndrome (Ræder et al., 2006) that is described in more detail in section 1.3.  
CNVs 
The probability of genomic rearrangements is increased with the constellation of a gene close 
to a homologous sequence. Thus, it can result in formation of a fusion gene that has different 
functional properties than the original. These fusion genes may be associated with disease 
(Harel and Lupski, 2017). 
CNVs of CEL have been reported, both a duplication and a deletion hybrid allele, which 
apparently are a result from nonallelic homologous recombination between CEL and CELP. 
The CEL duplication allele is not expected to translate into a protein due to a premature stop 
codon in CELP exon 8. However, the deletion hybrid allele (CEL-HYB) includes three VNTR 
repeats from the CEL pseudogene and encodes a CEL-CELP fusion protein that has been 
associated with chronic pancreatitis (Fig.1.7) (Fjeld et al., 2015).  
 
Figure 1.7 Copy number variants of the human CEL gene: duplication and a deletion variant.  a) Structure of the 
human CEL locus consisting of CEL and the pseudogene CELP. The gray shading of exon 2-7 in CEL corresponds to the 
exons missing in CELP.  b) Structure of a duplication allele and a deletion hybrid allele (CEL-HYB) of CEL. The duplication 
allele consist of exon 1, 8 and 9 from CELP and exon 10-11 from CEL. The deletion hybrid allele consists of exon 1-10 of 




1.3 Carboxyl ester lipase in human disease 
1.3.1 MODY8 
MODY8 is a type of monogenetic diabetes caused by a single base-pair deletion (DEL1 or 
DEL4) within the CEL-VNTR. The disease causes pancreatic exocrine dysfunction, 
lipomatosis and pancreatic cysts in addition to diabetes. The disease is autosomal dominant 
inherited (Johansson et al., 2018).  
The MODY8 syndrome was first discovered in a Norwegian family suspected to have 
monogenic diabetes (Ræder et al., 2006). The family members that were affected fulfilled the 
criteria for MODY, which are primary beta cell dysfunction and autosomal dominant diabetes 
detected before 40 years of age. However, the individuals also experienced, relatively early in 
life, fecal elastase deficiency due to pancreatic exocrine dysfunction, a high content of fat in 
the pancreas and repeated attacks of abdominal pain. By the age of 40, most of them had also 
developed diabetes and pancreatic cysts (Ræder et al., 2006, Ræder et al., 2014). The CEL-
DEL1 and DEL4 mutation results in an altered reading frame and an aberrant C-terminus of 
the CEL protein (Ræder et al., 2006). It has been suggested that MODY8 might be a protein 
misfolding disease due to the formation of both intra- and extra-cellular protein aggregates in 
cell model systems (Johansson et al., 2011, Molven et al., 2016). 
1.3.2 Chronic pancreatitis  
CEL-HYB is a fusion gene between CEL and CELP (Fig. 1.7) and is identified as a genetic 
risk factor for chronic pancreatitis. In patients from Germany and France with idiopathic 
chronic pancreatitis, the carrier frequency of CEL-HYB was increased by >5 fold, compared to 
the general population. However, even though the allele is a significant risk factor for 
developing chronic pancreatitis, the majority of the CEL-HYB carriers in the general 
population (about 1%) are expected to stay healthy (Fjeld et al., 2015, Molven et al., 2016). 
An association between longer CEL VNTR repeats and alcoholic chronic pancreatitis were 
reported by a Japanese study (Miyasaka et al., 2005), but the results could not be replicated in 
two larger studies from Europe (Ragvin et al., 2013, Fjeld et al., 2016). The varying results 
between European and Asian studies could be due to methodical issues or ethnic differences 
(Johansson et al., 2018).  
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1.3.3 Other pancreatic diseases  
The CEL gene has also been investigated in the context of pancreas cancer and type 1 
diabetes. One study looked at a possible connection between VNTR length and pancreas 
cancer, but no association was found (Dalva et al., 2017). Further, as mentioned above, 
associations between pancreas cancer and insertion variants in the CEL VNTR (Martinez et 
al., 2016) or the SNP (rs488087) in CEL exon 11 (Martinez et al., 2015) have been suggested. 
Insertion variants in the VNTR region have also been associated with exocrine dysfunction in 
type 1 diabetes patients (Ræder et al., 2006).  
1.3.4 Non-pancreatic diseases 
It have been shown in an HIV infected patient group that has a low/high VNTR repeat 
genotype is associated with accelerated disease progression, while a high/high VNTR repeat 
genotype is related to a slower disease progression (Stax et al., 2012).  
Another study compared serum lipid phenotype and CEL genotyping and revealed a 
correlation between the serum cholesterol profile and the number of VNTR repeats. Low-
density lipoprotein (LDL) cholesterol levels in individuals that carried at least one allele with 
less than 16 repeats, which are the most common, were significantly lower compared to 
individuals carrying two 16 repeats. The authors suggested as a possible explanation that CEL 
proteins with less proline-rich repeats are less well protected from degradation in the intestinal 
tract and/or secreted at a lower rate. Thus, the hydrolysis and uptake of cholesterol dietary 







2. Aims of the study 
The overall aim for this study was to understand the biological impact of insertion variants in 
the CEL gene. 
The specific objectives of the project were:  
1. To analyze the location and frequency of CEL insertion variants in human samples 
from a Norwegian pancreas biobank 
2. To establish a strategy for detecting CEL insertion variants both at the DNA and 
protein level 


















Table 3.1 Long-Range PCR and agarose gel electrophoresis 
Material Catalog Number Supplier 
E.Z.N.A ® Tissue DNA kit  D3396 OMEGA Bio-Tek 
NuSieve GTG (agarose) 50084 LONZA 
TBE Buffer x10 A3945, 1000 PanReac, AppliChem 
2XGC-Buffer 1 SD1432 TaKaRa 
dNTP-mix (2.5 mM each) SD0316 TaKaRa 
Betain solution (5M) B0300-1VL Sigma-Aldrich 
LaTaq (5U/μl) #RR02AG TaKaRa 
Ethidium Bromide (0.625 μg/μl) E406-15ml VWR 
Gel Loading Buffer G2526 Sigma-Aldrich 
1 Kb marker  #N3232S New England Biolabs 
 
 
Table 3.2 Sanger sequencing  
Material Catalog Number Supplier  
Sephadex ® G-50 Superfine G5050-50G Sigma-Aldrich 





4376486 Thermo Fisher Scientific 
 
BigDye Terminator v.3.1 Cycle 
sequencing kit 
4336917 Thermo Fischer Scientific 
Big Dye terminator v.1.1, v.3.1 
sequencing buffer 
4336697 Thermo Fischer scientific  
 
Big Dye terminator v.1.1 Cycle 
sequencing kit 
4336774 Thermo Fischer Scientific 
Illustra ™ExoProStar US77705V Sigma-Aldrich 
MicroAmp
TM
 Optical 96-well 
reaction plate  













Table 3.3 Plasmids  
Plasmids Variant  Description 
pcDNA 3 CEL-WT
1 
Plasmid expressing CEL-WT 
with 16 repeats of the VNTR 
pcDNA 3 CEL-INS9
1 
Plasmid expressing CEL with 




Plasmid expressing CEL with 




Plasmid expressing CEL 
lacking the VNTR region 
pCDNA 3 Empty vector Invitrogen  
1
The plasmids CEL-WT, CEL-INS9, CEL-INS11 and CEL-TRUNC were provided as a gift from 
Prof. M. Lowe, Washington University School of Medicine, St. Louis USA.  
 
 
Table 3.4 Plasmid preparation and purification  
Material Catalog Number Supplier 
imMedia
TM
 Growth Medium, agar, ampicillin Q60120 Thermo Fischer Scientific   
Lysogeny broth (LB) medium L7275-500TAB Sigma-Aldrich  
Super optimal broth with catabolite repression 
(SOC) medium 
15544-034 Thermo Fischer Scientific 
Ampicillin sodium salt  A9518-5G Sigma-Aldrich  
Plasmid Midi kit (100) 12245 Qiagen  
E.coli OneShot® TOP10 chemically competent 
cells 




Table 3.5 Cell culture 
Material Catalog Number Supplier 
Dulbecco`s Modified Eagle Medium 
(DMEM), high glucose, pyruvate  
41966-029 Thermo Fischer Scientific  
Fetal Bovine Serum (FBS) F7524-500ml Sigma-Aldrich 
Dulbecco`s Phosphate buffered saline (PBS) D8537-500ml Sigma-Aldrich 
Antibiotic Antimycotic 15240062 Thermo Fischer Scientific 







Table 3.6 Transient transfection  




Transfection reagent  
11668-019 Thermo Fischer Scientific 
OPTI-MEM (1x) Reduced 
Serum Medium 
31985-062-100 ml Thermo Fischer Scientific 
Complete
TM
 Mini EDTA-free 
protease inhibitors cocktail 
tablets 
11836170001 Sigma-Aldrich  




Microplates (6-well plate) 
08-772-29 Fischer Scientific 
 
 
Table 3.7 Immunocytochemistry 




Microplates (12-well plate) 
08-772-29 Fisher Scientific 
Poly-L-Lysine 0.01% solution P4832-50ml Sigma-Aldrich 
Triton x100 437002A VWR 
Slides, microscope S8902 Sigma-Aldrich 
Superfrost microscope slides Z692255-100EA Sigma-Aldrich 
Normal Goat Serum Control 10000C Thermo Fischer Scientific 
Paraformaldehyde (PFA) 818715 Millipore 
 
 
3.8 Immunohistochemistry  
Material Producer Catalogue number 
DAKO pen S2002 Agilent DAKO 
EnVision+ Kits, HRP. Mouse 
(DAB+) 
K400711-2 Agilent DAKO 
EnVision+ Kits, HRP. Rabbit 
(DAB+) 
K40111-2 Agilent DAKO 
















Table 3.9 SDS-PAGE and Western blot  
Material Catalog Number Supplier 
Pierce
TM
BCA Protein Assay kit 23225 Thermo Fischer Scientific 
NuPAGE ® LDS sample buffer 
(4x) 
NP0007 Thermo Fischer Scientific 
NuPage ® Sample Reducing agent 
(10x) 
NP0009 Thermo Fischer Scientific 
NuPage ® MOPS SDS Running 
buffer (20x) 
NP0001  Thermo Fischer Scientifc 
NuPage ® Novex 10 % Bis-Tris 
protein gels 1.0 mm, 10 well 
NP0301BOX  Thermo Fischer Scientific 
Precision Plus Protein
TM
 dual color 
standard 
161-0374 BioRad 
Magic Mark XP western protein 
standard 
LC5603 Thermo Fischer Scientific 
Immobilion-P membrane, PVDF, 
0.45μm  
IPVH07850 Millipore 
NuPAGE ® Transfer Buffer (20x) NP0006-1 Thermo Fischer Scientific 
Blocking grade blocker nonfat-dry 
milk 
170-6404 BioRad 
Phosphate buffer saline (PBS) 
tablets 
18912-014 Thermo Fischer Scientific 
Tween®20 8.22184.0500 Millipore 
Restore
TM
Western Blot Stripping 
Buffer 
21059 Thermo Fischer Scientific 
Pierce
TM
 ECL Plus Western 
Blotting Substrate 






















Table 3.10 Buffers and solutions 
Buffers and solutions Use Composition 
1xTBE buffer Gel electrophoresis For 1 L: 100 ml TBE buffer 10x from 
PanReac dissolved in 900 ml MilliQ 
water 
1% Agarose  Gel electrophoresis 1 gram NuSieve GTG (agarose) 
dissolved in 100ml 1xTBE buffer with 
0.625 μg/μl EtBr 
1 % Agarose gel Gel electrophoresis 50 ml 1 % agarose with 0.625 μg/μl EtBr 
NuPAGE® Transfer Buffer (1x) Western blot For 1 L: 50 ml NuPAGE ® Transfer 
buffer (20x) in 850 MilliQ dH2O and 10 
% methanol 
NuPage ® SDS MOPS buffer (1x) SDS-PAGE For 1 L: 50 ml NuPAGE® MOPS buffer 
(20x) in 950 MilliQ dH2O 
PBS-Tween 0.05 % Western Blot 1 PBS tablet dissolved in 500ml MilliQ 
dH2O with 0.05 % Tween®20 
5% milk Western Blot 5 gram blocking grade blocker nonfat-
dry milk and 100ml 0.05 % PBS-T 
1x Ripa Lysis Buffer Cell Lysis 1 ml 10xRIPA lysis buffer in 9 ml dH2O 
+ 1 tablet Complete
TM
 Mini EDTA-free 
protease inhibitors 
Blocking buffer Immunofluorescence  5% Normal goat serum  in washing 
buffer 
Washing Buffer (PBS 0.5 %) Immunofluorescence For 1L: 2 PBS tablets and 1 ml 
Tween®20 and 1000 ml MilliQ dH2O 
Permeabilization solution Immunofluorescence 15 μl Triton X-100 and 15 μl Tween 20 
dissolved in 14,97ml 1xPBS  
Paraformaldehyde (PFA) solution Immunofluorescence 6% PFA solution, 3 gram PFA dissolved 
in 50 ml MilliQ water + 5 drops of 1 M 
NaOH 
0.2 M Phosphate Buffer (PB) Immunofluorescence 0.2 M Na2HPO4 and 0.2 M NaH2PO4 
adjusted to pH 7.2  
Fixative Immunofluorescence 6% PFA + 0.2 M PB pH 7.2 (1:1) 
1mM EDTA – 10mM Tris buffer  
 
Immunohistochemistry 1,205g Tris + 0,395g EDTA to 1L dH2O, 
adjust pH to 9.0 
Antibody diluent Immunohistochemistry 0.05M Tris + 0.15M NaCl + 1 % BSA + 
0.02% Na-Azid + 0.0 % Tween, pH 











Table 3.11 Antibodies  
Antibody Catalogue number Supplier Usage 
Anti-CEL antibody 
(rabbit polyclonal) 
- Gift from Prof M. Lowe, 
Children's Hospital-
Washington University 
in St. Louis USA 
Primary (WB)* 





Gift from Prof O.Hernell, 
University of Umeå, 
Sweden 
Primary  (ICC)* 
Donkey anti-Rabbit IgG 
(H+L) Highly Cross-
Adsorbed Secondary 
Antibody, Alexa Fluor 
488 






Antibody, Alexa Fluor 
488 
 
A-11017 Thermo Fischer 
Scientific 
Secondary (ICC)* 





sc-2318 Santa Cruz 
Biotechnology 
Secondary (WB)* 
Goat anti-Rabbit IgG 
(H+L) HRP 





- Gift from Profs. 
Dominique Lombardo & 
Eric Mas, Marseille, 
France 




- Dominique Lombardo & 
Eric Mas, Marseille, 
France 




HPA052701 Sigma-Aldrich  Primary (IHC)* 
MACH 3 Rabbit HRP 
Polymer Medical 
RH531H Biocare Medical Secondary (IHC)* 
MACH 3 Rabbit Probe  RP531H  Biocare Medical Secondary (IHC)* 










Table 3.12 Technical equipment  
Instrument  Manufacturer  
Applied Biosystems Thermal Cycler 2720 Thermo Fischer Scientific 
GeneFlash Bio Imaging System Syngene 
3500xL genetic analyzer  Thermo Fischer Scientific 
NanoDrop ND-1000 Thermo Fischer Scientific  
Sceptre
TM
2.0 handheld automated cell counter Millipore 
LAS-1000 Imager Fujifilm 
Leica Confocal SP5 Lecia Microsystems 
Leica DM2000 LED Leica Microsystems 




Table 3.13 Analytical software 
Analytical software  Supplier 
SeqScape v. 2.7 Applied Biosystems 
Adobe Photoshop CS5 imaging  Adobe Photoshop 
LASV4.8 Leica 
ZEN 2011 Zeiss 











4.1 Patient material 
4.1.1 Pancreatic Biobank 
The human samples used in this study were from the Pancreas Biobank at Gade Laboratory 
for Pathology, Department of Clinical Medicine, University of Bergen. This biobank consist 
of blood and tissue samples from approximately 500 patients evaluated at the Department of 
Gastrointestinal Surgery, Haukeland University Hospital. The samples are collected on the 
basis of suspected or possible pancreatic tumor. The Research Ethics Committee (REK) of 
Western Norway has approved the study (no. 2013/1772) and the patients have given their 
informed consent. For 300 of the biobank samples, CEL VNTR length had been determined 
previously (Dalva et al., 2017), and the samples of this thesis were selected among those. 
 
4.2 Genotyping of the CEL – VNTR region  
4.2.1 Purification of human DNA samples 
Purification of genomic DNA from blood samples provided by the Pancreas Biobank was 
performed by Chief Engineer Solrun Steine using E.Z.N.A ® Tissue DNA kit.  
4.2.2 Polymerase Chain Reaction (PCR) 
Long range PCR was performed to amplify CEL exon 8-11 of genomic DNA from samples in 
the Pancreas Biobank. The PCR master mix was prepared as described in Table 4.1, including 
10 ng of DNA and CEL-specific primers. The primers are listed in Table 4.2 and the primer 
binding sites are illustrated in Figure 4.1 (for a more detailed illustration of the binding sites, 
see Appendix 1). The conditions for thermocycling are presented in Table 4.3, and were 









Table 4.1 PCR master mix 
Component  Volume (μl)  
2XGC-buffer 1 6.3125  
dNTP-mix (2,5mM each)  2  
L11F (20 μM) 0.375 
VNTR-R (20 μM) 0.375  
MilliQ dH2O 1.375  
Template (10 ng/μl) 1  
Betain (5M) 2.5  
LaTaq (5U/μl) 0.0625  
Total 14 μl 
 
Table 4.2 CEL primers for Long Range PCR and Sanger sequencing 









EF 5`-CACACACTGGGAACCCT-3`  
VNTR-R 5`-TCCTGCAGCTTAGCCTTGGG -3` 
 
Table 4.3 Thermal amplification cycles and conditions  
Step Temperature (°C) Time Number of cycles 
Initial denaturing 94 1 min  
Denaturing 1 94 20 sec  
Annealing 1 60 10 min   
Denaturing 2 94 20 sec  
Annealing 2 62 10 min  
Extension 72 10  min  
 4 ∞  
 
4.2.3 Agarose gel electrophoresis 
The Long Range PCR products were verified by agarose gel electrophoresis. Samples were 
separated on a 1 % agarose gel containing 0.625 μg/μl ethidium bromide. For each sample, 6 
μl of PCR product was mixed with 3.5 μl of 6x loading buffer before loading on the gel. In 
addition, 5 μl of 1 kb DNA marker was used as a molecular-weight size marker. The gel was 
run in 1xTBE buffer for ca. 1 hour and 15 minutes at 80 V. For visualization, the Gene Flash 





4.2.4 Sanger sequencing of the CEL VNTR region 
The long-range PCR products were treated with ExoSap before sequencing to remove excess 
of nucleotides. A total of 2 μl ExoSap were added to 5 μl of PCR product and incubated for 
15 min at 37 °C and 15 min at 80 °C.  
For Sanger sequencing, 2 μl of the ExoSap mix were used as template. The master mix for 
sequencing was prepared as described in Table 4.4. The primers are listed in Table 4.2 and the 
primer binding sites illustrated in Figure 4.1 (for a more detailed illustration of the binding 
sites, see Appendix 2). The conditions for thermocycling are presented in Table 4.5, and were 
performed on Applied Biosystems 2720 Thermal Cycler. The Sanger sequencing workflow is 
shown in Figure 4.2.  
 
Table 4.4 Master mix for sequencing  
Component  Volume (μl)  
Primer (5 μM) 0.25  
Betain (5M) 2  
MilliQ dH2O  2.75  
Seq.Buffer 2  
BD v.3.1 1  
Templat 2  
Total 10 μl 
 
 
Table 4.5 Thermal amplification cycles and conditions for sequencing  
Step Temperature (°C) Time Number of cycles 
Initial denaturing 96 10 min  
Denaturing 1 96 10 sec  
Annealing 1 58 5 sec   
Extension 60 4 min  







Figure 4.1 Primer binding sites. Primer binding sites for forward (L11F) and the reverse (VNTR-R) strand synthesis in the 
Long Range PCR reaction. L11F binds in intron 7, and VNTR-R binds in intron 11. L11F and VNTR-R amplify a region of 
approximately 3800 base pairs. Primer binding sites for forward (EF) and reverse (VNTR-R) for the two sequencing 
reactions performed. EF binds in exon 11 and VNTR-R binds in intron 11. EF and VNTR-R cover a region of approximately 
800 base pairs.  
The labelled sequencing products were purified by using Sephadex ® G-50 Superfine, which 
is a gel filtration medium. Sephadex ® G-50 Superfine was transferred to a multiscreen-HV 
filter plate together with 300 μl MilliQ water, and incubated at RT for two hours. Next, the 
excess of MilliQ water was removed from the gel filtration medium by centrifugation for 5 
min at 910 x g. The sequencing products were added 15 μl of milliQ and transferred to the 
packed multiscreen plate, placed on a sequencing plate, and centrifuged for 5 min at 910 x g. 
The purified sequencing products were analyzed on a 3500xL Genetic Analyzer. The 
sequences were evaluated manually.  
 







4.3 Preparation and sequencing of CEL-expressing plasmids  
4.3.1 Transformation of bacteria 
CEL-expressing plasmids (Table 3.3) were transformed into OneShot ® TOP10 chemically 
competent E.coli cells by the heat-shock method. For each transformation, 1 μl of plasmid 
was added to 35 μl of E.coli cells, incubated on ice for 30 minutes and heated for 30 seconds 
at 42°C. After the heat-shock, the cells were incubated on ice for 2 minutes. Next, 250 μl of 
pre-warmed SOC medium (42°C) was added to the vial before incubation at 37°C and 
shaking at 250 rpm. After 1 hour, 100-200 μl of the E.coli cells was spread onto agar plates 
with ampicillin (100 μg/ml). The plates were incubated overnight at 37°C.  
4.3.2 Bacterial cultures and plasmid purification using QIA filter Plasmid 
midi kit 
After transformation, one bacteria colony was picked and inoculated in a starting culture 
containing 5 ml LB medium and 50 μl of ampicillin (100 μg/ml). The starting culture was 
incubated at 37 °C with shaking (250 rpm) for 8 hours.  After 8 hours the starting culture was 
diluted 1:1000 in 25 ml with LB medium containing ampicillin (100 μg/ml). Then, the 
cultures were incubated for 16 hours at 37°C, shaking at 250 rpm. The next day, the cultures 
were transferred to a 50 ml falcon tube. Glycerol stocks were made for each culture. To make 
the glycerol stocks, 500 μl of bacterial culture were diluted with 500 μl of glycerol 50 %. The 
glycerol stocks were stored at -80 °C. The remaining cultures were centrifuged for 40 minutes 
at 4600 rpm. The supernatant was discarded, and the pellets were stored at -20°C until further 
use.  
Plasmid purification was performed according to the Qiagen(R) Plasmid Midi Kit (100) 
protocol. Buffers are those provided in the kit. Briefly, the bacterial pellet was resuspended in 
4 ml buffer P1 (added LyseBlue) and 4 ml buffer P2 was added. The mixture was incubated at 
room temperature (RT) for 5 minutes. Then, 4 ml of P3 buffer was added to the lysate. The 
lysate were poured in QIA filter cartridge and incubated at RT for 10 minutes.  The cell lysate 
were filtered into a buffer-equilibrated QIAGEN-tip. After washing, DNA was eluted with 5 
ml QF buffer. The eluted DNA was precipitated by adding 3.5 ml isopropanol and centrifuged 
at 4600 rpm for 45 minutes. After centrifugation, the DNA pellet was washed with 2 ml RT 
70 % ethanol and centrifuged at 4600 rpm for 15 minutes. The supernatant was removed and 
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the DNA pellet was air-dried for 5-10 minutes. DNA was re-dissolved in 200 μl TE buffer 
and stored at RT overnight. 
4.3.3 Determination of plasmid concentration and quality 
To determine the concentration of the purified plasmids, the absorbance of 1 μl of DNA was 
measured at 260 nm on a NanoDrop®ND-1000 spectrophotometer. The plasmid quality was 
verified by agarose gel electrophoresis. A total of 2 μl (600 ng) DNA was separated on a 1 % 
agarose gel with 0.625 μg/μl ethidium bromide to visualize the DNA migration in the gel.  
4.3.4 Sequencing of plasmid constructs 





 VNTR repeat, respectively. To verify these insertions, the plasmid constructs 
were sequenced by Sanger sequencing. To the PCR reaction mix (Table 4.6), 600 ng DNA 
was added together with one of the CEL primers listed in Table 4.7. The thermocycling 
conditions are the same as described in Table 4.5 
Table 4.6 Reaction mix for sequencing the CEL gene in plasmids 
Component  Volume (μl)  
Primer (5 μM) 0.25 
Betain (5M) 2 
MilliQ dH2O  2.75 
Seq.Buffer 2 




Table 4.7 Primers used for sequencing the plasmids 
 
 
Primer  Binding site Sequence (5`3`) 
T7 (forward) T7 promotor ATTATGCTGAGTGATATCCC 
BF (forward) Exon 2 GAAGCTGGGCGCCGTGT 
CF (forward) Exon 4 TCACCTTCAACTACCGT 
BR (reverse) Exon 6 TGGCTCGCCGGATG 
DF (forward) Exon 8 CCGCCGACATCGACTA 
CR (reverse) Exon 8 CTCCTCCGTGACTTTC 
DR (reverse) Exon 11 GCCGCTGTTTTCCGTA 
EF (forward) Exon 11 CACACACTGGGAACCCT 
BGH (reverse) BGH polyadenylated sequence ATCTTCCGTGTCAGCTCC 
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The plasmid sequencing products were purified by the Xterminator kit. A total of 45 μl of 
SAM solution buffer and 10 μl Xterminator mix was added to a sequencing plate. The 
sequencing products were added 15 μl of MilliQ water, and 10 μl of the volume was added to 
the sequencing plate. The plate was shaken for 20 minutes at 1800 rpm, and centrifuged for 2 
minutes at 1000 x g. The samples were analyzed on a 3500xL genetic analyzer. The 
sequences were evaluated with SeqScape software v. 2.7.   
 
4.4 Cell culturing and transfection 
4.4.1 Culturing of human embryonic kidney cells 293 (HEK293) 
For the cell culture experiments, HEK293 human embryonic kidney cells were employed 
(Clontech catalog no. 632180). The cells were cultured in Dulbeccos Modified Eagle`s 
medium (DMEM). DMEM was supplemented with 10 % fetal bovine serum and 100 U/ml of 
antibiotics antimycotic. The cells were grown at 37° with 5 % CO2, in a humidified 
atmosphere. 
4.4.2 Thawing 
HEK293 cells were thawed quickly in a 37°C water bath. The cells were transferred to a 15 
ml tube with 12 ml of pre-warmed (room temperature) DMEM, and centrifuged at 1000 rpm 





) pre-warmed DMEM.  
4.4.3 Sub-culturing and seeding 
To passage the HEK293 cells, DMEM was removed and cells were washed in phosphate 
buffered saline (PBS). The PBS was removed and 1 ml trypsin EDTA (0.05%) was added to 
detach cells from the surface. The cells were resuspended in growth medium and further 
diluted in a suitable amount of DMEM before transferred to a T75 cm
2
 flask. The flask was 
then filled up to 12 ml with fresh DMEM. PBS, DMEM and trypsin were all pre-warmed to 
RT before washing/passaging cells. For sub-culturing and seeding, only T75cm
2
 flasks were 




HEK293 cells were grown to 80-90 % confluency in a T75cm
2
 flask prior to freezing. 
Complete growth medium was removed and cells were washed with 7 ml pre-warmed PBS. 
The PBS was removed, 3 ml Trypsin EDTA (0.05%) was added and the cells were 
resuspended in 5 ml DMEM. Next, the cells were transferred to a 15 ml tube and centrifuged 
for 5 minutes at 1000 rpm. The supernatant was removed and the pellet was resuspended in 3 
ml freezing medium (1 ml of 100% DMSO and 9 ml complete media). The cells were divided 
into 3 vials containing 1 ml each. The freezing vials were transferred to a CoolCell
™
 LX 
Freezing Container and stored at -80°C o/n. For long-time storage, the vials were stored in a 
liquid nitrogen tank. 
4.4.5 Transient transfection of HEK293 cells 
Prior to transfection, cells were grown to 60-70 % confluency in a T75cm
2
 flask. The cells 
were washed in PBS, trypsinated and resuspended in 4-5 ml of DMEM before transferred to a 
15 ml tube. Five μl of the resuspended cells were diluted in 495 μl of PBS (1:100) and 
counted with a Scepter™ 2.0 Cell Counter. Cells were seeded in 6-well plates (1x105 cells per 
well) and grown for 72 hours or in a 12-well plate (2.5x10
5
 cells per well) and grown for 24 
hours. 
The total amount of DNA was 4 μg in 6-wells and 0.5 μg in 12-wells, for each transfection. 
DNA and Lipofectamine®2000 were both diluted in 250 μl of OPTIMEM. Lipofectamine and 
OPTIMEM were incubated for 5 minutes at RT. After the incubation, the DNA was 
transferred to the tube containing Lipofectamine®2000 and incubated for 20 minutes in room 
temperature. After 20 minutes, the DNA-lipid mix was added to the cells and incubated for 4-
6 hours before the cells were washed, and fresh growth media was added. The cells were 
further grown for 48 hours at 37°C and 5 % CO2. 
4.4.6 Preparation of analytical fractions; medium, cell lysate, and cell pellet  
Post-transfection, 1 ml of media was collected and centrifuged at 18 000 x g for 5 minutes at 
4°C. The supernatant was collected and analyzed (denoted the ‘medium fraction’). The 
remaining medium was removed and the cells were washed with PBS and added 150 μl of 
ice-cold RIPA Lysis Buffer containing protease inhibitors (1 tablet per 10 ml of 1x RIPA 
buffer). A cell scraper was used to detach the cells from the plate surface. The cells were 
collected and incubated for 30 minutes on ice, before centrifuged at 18 000 x g at 4°C for 15 
minutes. The supernatant was transferred to a new vial and analyzed (denoted the ‘lysate 
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fraction’). The remaining pellet was washed with 150 μl PBS and centrifuged at 18 000 x g 
for 15 minutes and 4 °C. This washing step was performed twice. Finally, the pellet was 
added 100 μl of 4x LDS loading buffer, denatured for 5 minutes at 95°C and analyzed 
(denoted the ‘pellet fraction’). All fractions were stored at -80°C if not analyzed immediately.  
4.4.7 Determination of protein concentration  
The protein concentration of the lysate fraction was determined by using a PierceTMBCA 
Protein Assay kit. Four μg of cell lysate were subjected to Western blotting. For the medium 
and pellet fractions, the volume loaded onto the SDS gel was the same as for the 
corresponding lysate. 
  
4.5 Western blotting  
4.5.1 SDS-PAGE 
For SDS-PAGE, the medium and lysate samples were prepared as described in Table 4.8. 
Before loading, the samples were denatured at 56°C for 15 minutes on a heating block. For 
the pellet fraction, samples were prepared as described above. Medium (20 μl), lysate (20 μl) 
and pellet (2-5 μl) samples were loaded on 10 % NuPage Bis-Tris gels (1mm, 10 well) and 
separated by electrophoresis in a XCell SureLock
TM
 Mini-Cell system. Four μl of Precision 
Plus Protein Dual Color and 2 μl of Magic Mark XP were used as protein size markers. The 
gels were run in 1x NuPage MOPS buffer for 15 minutes at 90V and 180 V for 60 minutes.  
 
Table 4.8 Sample preparation for SDS-PAGE 
Component Volume (μl) 
Reducing agent 10X 2  
LDS 4X 5 
Sample/ddH2O 13  
Total volume 20 μl 
 
4.5.2 Transfer  
After SDS-PAGE, the proteins were transferred from the NuPage Bis-Tris gel to a 
Polyvinylidene fluorid (PVDF) membrane by Western blotting in an XCell Blot Module 
chamber according to the manufacturer’s instructions. The PVDF membrane was activated in 
100 % methanol for 1 minute before use. The blotting was performed at 30 V for 60 minutes 
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in 1x NuPage transferbuffer with 10 % methanol. Thereafter the PVDF membrane was 
blocked in 5 % milk (Table 3.10) for 1 hour at room temperature. The membrane was then 
incubated with primary antibodies diluted in 1% milk o/n at 4°C. The following primary 
antibodies were used: anti-PAVIRF (1:5000); anti-PRAAHG (1:5000); anti-CEL (1:10 000). 
As loading control, the primary antibody anti-GAPDH (1:1000) was included. The next day, 
the membranes were washed 3x5 minutes with PBS-T (0.05%) and incubated with HRP-
conjugated secondary antibodies for 1 hour at RT. Secondary antibodies were diluted 1:5000 
or 1:10000. Finally, the membranes were washed 1x15 minutes and 3x5 minutes with PBS-T 
(0.05 %) before developed by using Pierce ECL Plus Western Blotting Substrate kit. The 
signals were detected with a LAS 1000 imager and quantification of protein bands was 
performed using the Image Gauge v4.0 software (Fujifilm).  
4.5.3 Statistical analysis 
The p-value was calculated using a two-tailed T-test. CEL-WT was compared to CEL-
TRUNC in the lysate and in the medium fraction. In the pellet fraction, CEL-WT was 
compared to CEL-INS9, CEL-INS11 and CEL-TRUNC. The significance level was defined 
as 0.05. To determine the p-value, the statistical calculator from the webpage 











4.6 Immunostaining and confocal imaging  
Cells were seeded in 12-well plates (2.5x10
5
 cells per well) on coverslips coated with Poly-L-
lysine. After transfection, cells were washed with pre-warmed PBS and fixed in 3% 
paraformaldehyde (500 μl per 12-well) for 20 minutes. 
4.6.1 Staining  
After fixation, the cells were washed 3x5 minutes with washing buffer (PBS 0.5 %), before 
being permeabilized (Table 3.10) for 20 minutes. Next, blocking-buffer (5% goat serum in 
PBS 0.5 %) was added for 30 minutes before cells were incubated with 40 μl of primary 
antibody for 2 hours at RT. The primary antibodies used were As20.1 (1:200), anti-PAVIRF 
(1:5000) or anti-PRAAHG (1:5000) diluted in blocking-buffer. After incubation with primary 
antibody cells were washed 3x10 minutes in washing buffer. Next, 40 μl conjugated 
secondary antibodies donkey anti-rabbit Alexa Fluor 488 or anti-mouse Alexa Fluor 488 
(1:200 in blocking buffer) was added to each coverslip. Cells were incubated for 1 hour with 
secondary antibody, before they were washed 3x10 minutes with washing buffer. Finally, the 
cells were quickly rinsed three times with phosphate buffered saline. Coverslips were 
mounted on glass slides in 10 μl of Prolong Gold Antifade Solution with 4′,6-Diamidine-2′-
phenylindole dihydrochloride (DAPI). Slides were allowed to cure at room temperature 
overnight and then stored at -20°C.  
4.6.2 Confocal imaging  
The samples were examined with a Leica TCS SP5 confocal microscope (Leica 
Microsystems) with a 65×/NA 1.4 Plan-Apochromat oil-immersion objective, ~1.2 Airy unit 
pinhole aperture and the appropriate filter combinations. Images were acquired with Diode 
405 and Argon 488 lasers and processed with Adobe Photoshop CS5 image software (Adobe 








Formalin Fixed Paraffin Embedded (FFPE) pancreatic tissue sections (3-5μm) were placed 
onto SuperFrost Plus Adhesion slides and dried overnight at 56°C. The next day, the slides 
were deparaffinized in xylene for 2x5 minutes and rehydrated with decreasing concentrations 
of ethanol, 2x5 minutes for each (100 %, 96 % and 80 %) and lastly washed with dH2O and 
PBS-T (0.05%). All washing steps were performed on a rocking platform. After washing, the 
tissue sections were incubated with Tris-EDTA (pH 9) in a pressurized heating chamber at 
120 °C for 1 minute and cooled down in running tap water. The tissues were delineated with a 
Dako pen and incubated with primary antibodies in a humidity chamber overnight at 4 °C. 
Primary antibodies that were used were anti-PRAAHG (1:5000), anti-PAVIRF (1:5000) and 
anti-CEL (1:100). The next day, the primary antibody was removed and the tissues were 
rinsed in dH2O and washed with PBS-T (0.05%) for 4x15 minutes. The slides were incubated 
with DAKO peroxidase for five minutes in room temperature, to block endogenous 
peroxidase activity, rinsed with dH2O and washed 3x5 minutes in PBS-T (0.05%).  
As secondary antibody a kit from Biocare Medical was used. It included MACH3 probe and 
MACH3 HRP polymer. The probe binds specifically to the primary monoclonal antibody and 
the polymer horseradish-peroxidase molecule binds specifically to the probe (Biocare 
Medical). The tissues were incubated with the MACH3 probe for 20 minutes, rinsed in dH2O 
and washed in PBS-T (0.05%) for 3x5 minutes. Next, the slides were incubated with MACH3 
HRP polymer for 20 minutes before they were rinsed in dH2O and washed in PBS-T (0.05%) 
for 3x5 minutes  
Visualization was performed by 3,3`-diaminobenzidine (DAB).  The sections were stained 
with hematoxylin for 1 minute in room temperature. Finally, the slides were dehydrated in 
increasing concentrations of ethanol (80 % – 96 % – 100 %) and xylene, one minute in each. 
Tissues were mounted in mounting media. To obtain images of the tissue sections, a Leica 
DM2000LED microscope with the LASV4.8 software or a Leica DMLB microscope with the 






5.1 Screening for CEL insertions in samples from the Pancreas 
Biobank  
The Pancreas Biobank includes both DNA samples and pancreatic tissue sections from most 
of the patients and thereby makes it possible to study CEL insertions both at DNA and protein 
levels. To investigate CEL insertions at the DNA level we used DNA sequencing. 
5.1.1 Amplification of CEL Exon 8-11 
Due to the high sequence similarity between CEL and the nearby pseudogene CELP, one has 
to be careful when performing PCR analysis on the CEL gene. Consequently, before 
sequencing, we amplified the CEL exon 8-11 region using a forward primer (L11F) that binds 
in intron 7 of CEL which is not present in the pseudogene (Fig. 4.1). This PCR product was 
later used as a template for the sequencing reaction. 
To amplify CEL exon 8-11, a long-range PCR was performed on genomic DNA samples from 
the Pancreas Biobank. The PCR products were separated on a 1 % agarose gel to confirm that 
the amplification had been successful. In Figure 5.1, the molecular bands have the expected 
length of CEL exon 8-11 at approximately 3.8 kb.  
 
 
Figure 5.1 CEL amplification (exon 8-11) products from long-range PCR visualized by agarose gel electrophoresis. A 
total of 10 ng genomic DNA from the Pancreas Biobank were loaded. The sizes of the products are about 3.8 kb. The gel 




5.1.2 Sanger sequencing of the CEL VNTR region  
To search for insertions in the CEL-VNTR region, CEL exon 11 was sequenced by Sanger 
sequencing.  The sequence print-outs were evaluated manually. Figure 5.2A shows an excerpt 
of the VNTR region of CEL where repeat 9-10 is marked. Figure 5.2B displays a close-up 
image of the same repeat 9-10 and the insertion of a cytosine was found in a region with a 
high content of cytosines (C). For comparison, repeat 9-10 from a WT sequence is shown in 
Fig. 5.2C. A total of 50 samples were sequenced and checked for insertions (Table 5.1). Five 
samples with insertion in repeat 9 (INS9), one sample with an insertion in repeat 10 (INS10) 
and one sample with an insertion in repeat 12 (INS12) were observed. 
The single nucleotide polymorphism (SNP) denoted rs488087 is the only common nucleotide 
substitution present in the CEL VNTR. This variant is a change from a cytosine (C) to a 
thymine (T) in position 12 in VNTR repeat 2. Of the 50 sequenced samples, 24 subjects with 
C/C, 21 with C/T and 5 with T/T were observed. This corresponded to a genotype frequency 
of 0.48 for C/C, 0.42 for C/T, and 0.10 for T/T. The allele frequency for C and T was 0.69 and 
0.31, respectively.  
 
Figure 5.2 Screening for insertions in the VNTR region of CEL. Genomic DNA from the Pancreas Biobank was 
sequenced to look for insertions in the VNTR region of CEL. A) An excerpt of a sequence in the VNTR region where repeat 
9 and 10 are highlighted. B) Enlarged picture of repeat 9 and 10 in part A. The red arrow points to the site of the insertion of 
an extra cytosine in repeat 9. C) A WT sequence devoid of cytosine (C) insertion in repeat 9.  
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Table 5.1 Sequenced genomic DNA samples from the Pancreas Biobank. The table shows a summary of the sequenced 
genomic DNA samples from the Pancreas Biobank with VNTR length, SNP status in position 12 of VNTR repeat 2, insertion 
status (marked in red) and the diagnosis of the patients. Samples with VNTR length of 13 are indicated by grey shading. 
PDAC = pancreatic ductal adenocarcinoma, C= cytosine, T= thymine. INS9 = insertion in repeat 9, INS10 = insertion in 
repeat 10 and INS12 = insertion in repeat 12.   
 
Sample Id VNTR length rs488087 in second VNTR repeat INS status Diagnosis
42 14/15 C/C WT Benign tumor or other pancreatic disease
43 16/16 C/C WT Benign tumor or other pancreatic disease
44 16/16 C/T WT PDAC
46 16/16 C/T WT PDAC
47 15/16 C/C WT PDAC
48 16/16 C/T INS12 PDAC
49 16/16 C/C WT PDAC
50 15/21 C/C WT PDAC
51 16/16 C/T WT PDAC
52 13/14 C/T INS9 PDAC
53 16/16 C/T WT PDAC
56 15/16 C/C WT PDAC
57 13/16 C/C WT PDAC
58 14/16 C/C WT PDAC
60 16/16 C/T WT Benign tumor or other pancreatic disease
61 16/16 C/C WT PDAC
62 16/16 C/T WT PDAC
63 15/16 C/C WT PDAC
64 15/16 C/C WT Benign tumor or other pancreatic disease
65 15/16 C/C WT PDAC
66 12:15 C/C WT Benign tumor or other pancreatic disease
67 16/16 C/C WT PDAC
68 16/16 C/C WT Benign tumor or other pancreatic disease
69 15/16 C/T WT Benign tumor or other pancreatic disease
70 14/15 C/T WT PDAC
71 14/16 C/T WT Benign tumor or other pancreatic disease
73 16/16 C/C WT PDAC
75 16/16 C/T WT Benign tumor or other pancreatic disease
76 13/17 T/T INS9 PDAC
77 16/16 C/T WT Benign tumor or other pancreatic disease
78 16/17 C/C WT PDAC
79 15/15 C/T WT PDAC
80 13/14 C/T INS9 Benign tumor or other pancreatic disease
82 15/16 C/C WT PDAC
83 14/16 C/T WT PDAC
84 15/17 C/C WT PDAC
85 16/16 C/C WT Benign tumor or other pancreatic disease
86 16/16 T/T WT PDAC
88 14/15 C/T INS10 PDAC
89 12:16 C/C WT Benign tumor or other pancreatic disease
90 16/16 C/C WT PDAC
92 15/15 C/C WT Benign tumor or other pancreatic disease
93 12:16 C/C WT Benign tumor or other pancreatic disease
94 16/16 C/T WT Benign tumor or other pancreatic disease
95 13/16 C/T INS9 Benign tumor or other pancreatic disease
96 16/16 T/T WT PDAC
97 15/16 C/T WT PDAC
98 16/16 T/T WT Benign tumor or other pancreatic disease
99 16/16 T/T WT Benign tumor or other pancreatic disease
100 13/16 C/T INS9 PDAC
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5.1.3 Insertion in repeat 9 is linked to a VNTR length of 13 
Among the 50 screened samples, we observed that all samples with an insertion in repeat 9 
had a VNTR length of 13 (Table 5.1). To investigate this relationship further, all remaining 
DNA samples from the Pancreas Biobank with a VNTR length of 13, either homo- or 
heterozygous, were sequenced (25 samples) (Table 5.2).  
Table 5.2 Sequenced genomic DNA samples from the Pancreas Biobank with VNTR length of 13. All genomic DNA 
samples in the Pancreas Biobank with a VNTR length of 13 were sequenced. The table shows a summary of remaining 
samples with a VNTR length of 13 plus the six samples from Table 5.1, the SNP status in position 12 in repeat 2, insertion 
status (marked in red) and the diagnosis of the patient. PDAC = pancreatic ductal adenocarcinoma, C= cytosine, T= thymine. 




Sample Id. VNTR length
rs488087 in second 
VNTR repeat INS status Diagnosis
3 13/16 T/T INS9 PDAC
7 13/15 C/T INS9 Benign tumor or other pancreatic disease
31 13/14 C/C WT Benign tumor or other pancreatic disease
52 13/14 C/T INS9 PDAC
57 13/16 C/C WT PDAC
76 13/17 T/T INS9 PDAC
80 13/14 C/T INS9 Benign tumor or other pancreatic disease
95 13/16 C/T INS9 Benign tumor or other pancreatic disease
100 13/16 C/T INS9 PDAC
101 13/16 C/C WT PDAC
103 13/15 T/T INS9 Benign tumor or other pancreatic disease
106 13/16 C/C WT Benign tumor or other pancreatic disease
109 13/15 C/T INS9 PDAC
113 13/13 T/T INS9 Benign tumor or other pancreatic disease
128 13/17 T/T INS9 Benign tumor or other pancreatic disease
132 13/16 C/T INS9 Benign tumor or other pancreatic disease
140 13/16 T/T INS9 PDAC
143 13/14/16 C/C WT Benign tumor or other pancreatic disease
150 13/16 T/T INS9 Benign tumor or other pancreatic disease
153 13/13 C/T INS9 PDAC
164 13/16 T/T INS9 Benign tumor or other pancreatic disease
174 13/16 C/T INS9 Benign tumor or other pancreatic disease
188 13/15 C/C WT PDAC
209 13/16 C/T INS9 Benign tumor or other pancreatic disease
210 13/16 C/T INS9 Benign tumor or other pancreatic disease
220 13/16 C/C WT PDAC
236 13/16 C/T INS9 Benign tumor or other pancreatic disease
240 13/16 C/T INS9 PDAC
258 13/13 T/T INS9 Benign tumor or other pancreatic disease
265 13/15 C/T INS9 PDAC
276 13/16 C/C WT PDAC
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Of the additional 25 cases with a VNTR length of 13, 18 samples had an insertion in repeat 9. 
In total, including INS9 cases from Table 5.1 and Table 5.2, 31 samples had a VNTR length 
of 13. Of these, 23 cases, (74%) had an insertion in the 9
th
 repeat of the VNTR region 
suggesting a high association between VNTR repeat 13 and the insertion.  
Figure 5.3 shows a panel of four sequences (A-D) from repeat 8-9 in the VNTR region of 
CEL, comparing a WT sequence, a 13 repeat sequence without INS9, and a heterozygous and 
homozygous sequence with INS9. The homozygous sequence (D) displays a cleaner insertion 
peak, than the heterozygous sequence (C).  
The 13 repeat allele was not linked to rs488087. However, all the INS9 cases had the T allele, 
which shows a possible association between the T allele and INS9 (Table 5.2). 
 
 
Figure 5.3 Comparison repeat 8 and 9 in sequences with and without INS9. A) WT sequence with a 16/16 VNTR. B) 
Sequence with 13/16 VNTR, but no insertion. C) Sequence with 13/15 where the red arrow points to the site of insertion. D) 








5.2 New tools for analyzing insertion variants of CEL 
To evaluate and compare the biological function of insertion variants towards the CEL-WT, 
plasmids expressing different protein variants of CEL (CEL-WT, CEL-INS9, CEL-INS11 and 
CEL-TRUNC) were used. These plasmids were all a generous gift from (M. E. Lowe and X. 
Xiao, St. Louis, USA). CEL-TRUNC was included to observe the biological function of CEL 
without the VNTR region. An empty vector (EV) was included as a negative control. The 
protein structure of all the CEL variants are presented in Fig. 5.6. All antibodies used in this 
chapter are specified in Materials (Table 3.11). 
5.2.1 Transformation and purification of plasmids expressing different 
variants of CEL and determination of DNA purity 
Plasmids expressing different variants of CEL (CEL-WT, CEL-INS9, CEL-INS11, CEL-
TRUNC) or EV were transformed into E.coli bacteria. After transformation, the plasmids 
were purified and analyzed by optical density (OD) measurements to estimate the DNA 
concentration. In addition, the plasmids were separated on a 1% agarose gel to estimate the 
quality and confirm that the plasmids were intact (Fig. 5.4). 
 
 
Figure 5.4 Visualization of plasmids expressing different variants of CEL. Plasmids expressing CEL-WT, CEL-INS9, 
CEL-INS11, CEL-TRUNC and an empty vector (EV) were separated on a 1 % agarose gel stained with ethidium bromide. 




5.2.2 Sequencing of plasmids expressing CEL-INS9 and CEL-INS11 
To verify that the plasmids expressing CEL-INS9 and CEL-INS11 had the desired mutation in 
the correct site, the plasmids were sequenced by Sanger sequencing and evaluated by the 
program SeqScape. Figure 5.5A shows the sequences of repeat 8 and 9 of the CEL-INS9 and 
CEL-INS11 expressing plasmids. Figure 5.5B shows the sequence of repeat 10 and 11 of the 




Figure 5.5 Sequencing of plasmids expressing CEL-INS9 and CEL-INS11. Plasmids expressing INS9 and INS11 were 
sequenced to verify that they had the desired mutation in the right site. A) Repeat 8 and 9 for CEL-INS9 and CEL INS11. 
The panel shows that INS9 has an insertion of a cytosine in repeat 9 (red arrow), while INS11 has not. B) Repeat 10 and 11 
for CEL-INS9 and CEL-INS11. The panel shows that INS11 has an insertion of a cytosine in the 11th repeat (red arrow), 





5.2.3 Testing of tail-specific antibodies for the CEL-WT and the CEL 
insertion variants by western blotting 
We were provided with antibodies that were specific towards the CEL-WT tail and the CEL-
insertion tail (Fig. 5.6). To test these antibodies, HEK293 cells were transiently transfected 
with plasmids expressing CEL-WT, CEL-INS9, CEL-INS11, CEL-TRUNC or EV (Fig. 5.6). 
After 72 hours of transfection, the lysate fractions were collected and analyzed by three 
separate SDS-PAGE and western blots. Immunodetection was performed by a polyclonal 
CEL-specific antibody (anti-CEL), the CEL insertion-tail specific antibody (anti-PRAAHG) 
and the CEL WT-tail specific antibody (anti-PAVIRF), Anti-CEL detected all the CEL-
variants (WT, INS9, INS11 and TRUNC), anti-PRAAHG detected CEL-INS9 and INS11 and 
anti-PAVIRF detected the CEL-WT (Fig. 5.7). 
 
Figure 5.6 Overview of the various CEL varaints tested and their epitopes for the specific antibodies. A) CEL-WT 
consists of 16 repeats in the VNTR, and the C-terminal ends with the 11 amino acids KEAQMPAVIRF. B and C) CEL-
INS11 and CEL-INS9 are insertion variants of CEL and have a truncated C-terminal that ends with the amino acids 
PRAAHG. D) TRUNC is an artificially created variant of CEL that does not contain the VNTR region. The WT-tail specific 
antibody binds to the six last amino acids in the C-terminal of CEL-WT, PAVIRF. The insertion-tail specific antibody binds 
to the six last amino acids in the C-terminal of the insertion variants, PRAAHG. The CEL-specific antibody binds to the 




Figure 5.7 Testing of CEL specific antibodies by western blot. HEK293 cells were transiently transfected with different 
variants of CEL. After transfection, the lysate fractions were collected and further used in SDS-PAGE and western blot with 
three different antibodies, anti-CEL, anti-PRAAHG and anti-PAVIRF. Anti-PRAAHG is an insertion tail specific antibody, 
while anti-PAVIRF is a WT-tail specific antibody. For comparison, an antibody towards the globular domain of CEL (anti-
CEL) was included.  
 
5.2.4 Testing of CEL-WT and CEL-INS tail-specific antibodies by 
immunocytochemistry 
To observe the reactivity of the specific tail antibodies by immunocytochemistry, HEK293 
cells were transiently transfected with plasmids expressing CEL-WT, CEL-INS9, CEL-
INS11, CEL-TRUNC or EV. Cells were transfected for 24 hours, before they were fixated 
and analyzed by immunostaining and confocal imaging. All variants were stained with an 
anti-CEL-specific antibody, the WT tail-specific antibody (anti-PAVIRF) and the insertion 
tail-specific antibody, anti-PRAAHG . 
The antibody directed towards the CEL globular domain (As20) displayed reactivity to all 
variants (Fig. 5.8). Further, as expected, the anti-PRAAHG antibody only displayed reactivity 
to CEL-INS9 and CEL-INS11 (Fig. 5.10). In contrast, the WT-tail specific antibody that 
should only have reactivity to the HEK293 cells expressing CEL-WT also showed reactivity 
to both INS-variants and CEL-TRUNC, which lacks the WT-tail (Fig. 5.9A). However, the 
positive staining in Figure 5.9A may be misleading, since the positive reactions only occurred 




Figure 5.8 CEL immunostaining using an antibody directed towards the CEL globular domain (anti-As20). HEK293 
cells were transiently transfected with CEL-WT, CEL-INS9, CEL-INS11 and CEL–TRUNC. An empty vector (EV) was 
included as control. Post-transfection, the cells were subjected to immunostaining using the CEL specific As20-antibody and 
secondary antibody AlexaFluor-488 (green). The chromosome counterstain (DAPI) is shown in blue. Each image represents 







Figure 5.9 CEL immunostaining using a WT-tail specific antibody (anti-PAVIRF). A) HEK293 cells were transiently 
transfected with CEL-WT, CEL-INS9, CEL-INS11 and CEL – TRUNC. Empty vector (EV) was included as a negative 
control. 48 hours post-transfection, the cells were subjected to immunostaining using the Anti-PAVIRF antibody. As a 
secondary antibody, AlexaFluor-488 (green) was used. The chromosome counterstain (DAPI) is shown in blue The scale bar 
represents 10 μm. B) Overview images of CEL-INS9, CEL-INS11, CEL-TRUNC and EV stainings. Each image represents a 





Figure 5.10 CEL immunostaining using an INS-specific tail-antibody (anti-PRAAHG). HEK293 cells were transiently 
transfected with CEL-WT, CEL-INS9, CEL-INS11 and CEL-TRUNC. Empty vector (EV) was included as a negative 
control. 48 hours post-transfection, the cells were subjected to immunostaining using the anti-PRAAHG antibody. As a 
secondary antibody, AlexaFluor-488 (green) was used. The chromosome counterstain (DAPI) is shown in blue. Each image 




5.3 Testing tail-specific antibodies on human pancreatic tissues  
We next wanted to determine whether the tail-specific antibodies also could be used to detect 
CEL-variants in human pancreatic tissue. Formalin fixed paraffin embedded sections from 
three different patients from the Pancreas Biobank were selected for testing.  
5.3.1 Testing CEL tail-specific antibodies with immunohistochemistry on 
pancreatic ductal adenocarcinoma cases 
Immunohistochemistry were performed on formalin fixed paraffin embedded morphological 
normal appearing tissues from patients with pancreatic ductal adenocarcinoma. This was 
performed to observe the reactivity of the CEL-insertion (anti-PRAAHG) and the CEL-WT 
(anti-PAVIRF) tail-specific antibodies. Figure 5.11 show three samples from Table 5.2 (153, 
240 and 220), all stained with anti-PRAAHG, anti-PAVIRF and anti-CEL. All samples 
showed reactivity to anti-CEL and anti-PAVIRF. Number 153 and 240 were insertion-
positive and displayed reactivity to anti-PRAAHG. Number 220 was insertion-negative and 
was expected to be negative, but interestingly still had some isolated areas that were anti-
PRAAHG positive. 
 
Figure 5.11 Reactivity of pancreas tissues to CEL specific antibodies. Morphological normal appearing tissue sections 
from pancreas cancer patients were stained with anti-CEL (globular domain-specific, Sigma), anti-PAVIRF (WT tail-
specific) and anti-PRAAHG (insertion tail-specific). Positive CEL staining is shown in brown. Nr. 153, 220 and 240 




5.3.2 Testing of CEL tail-specific antibodies with immunohistochemistry on 
pancreatic tissue sections from patients with non-cancerous disease 
We observed that sample nr. 220 (Fig. 5.11) had restricted positive areas with anti-PRAAHG. 
However, all the cases in Figure 5.11 were PDAC cases and we wondered if this observation 
was specific for cancer patients. To observe the reactivity of non-pancreatic cancer cases with 
the tail-specific antibody anti-PRAAHG, immunohistochemistry was performed on four 
formalin fixed paraffin embedded human tissues from pancreas. The four non-pancreatic 
cancer cases all had clusters of cells or single cells that showed reactivity to anti-PRAAHG 
(Fig. 5.12). An insertion-positive pancreatic cancer case was included as a positive control 
(Nr. 153, Table 5.2).  
 
 
Figure 5.12 Reactivity of pancreas tissues in non-cancer patients with the insertion tail-specific antibody. Non-
pancreatic cancer tissues (subject A-D) were stained with the insertion tail-specific antibody (anti PRAAHG) (brown). An 
insertion-positive pancreatic cancer case (number 153 in table 5.2) was included as a positive control. Scale bar is 50 µm. 
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5.4 The effect of insertions in the CEL-VNTR region on protein 
secretion and aggregation 
Finally, we wanted to investigate the impact of the insertion variants in a cellular model 
system to observe if the insertion variants had a potential pathogenic effect compared to the 
CEL-WT.  
HEK293 cells were transiently transfected with plasmids expressing different variants of 
CEL, namely CEL-WT, CEL-INS9, CEL-INS11 and CEL-TRUNC (Fig. 5.6). CEL-TRUNC 
was included to observe the effect of protein secretion and aggregation with an absent VNTR 
region. Cells transfected with an empty vector (EV) was included as a negative control. After 
48 hours of transfection, cell medium, lysate and pellet fractions were isolated and analyzed 
by SDS-PAGE and western blotting. GAPDH was used as a loading control. Immuno-
detection was performed using a polyclonal CEL-specific antibody (Xiao et al., 2016).  
Three independent experiments were performed (Fig. 5.13A) and quantification analysis of 
the Western blots results are shown in Figure 5.13B. The diagram shows that INS9 and INS11 
are approximately equally detected in the lysate and the medium, but in the pellet there is a 
higher content of INS9 than of INS11 and CEL-WT. CEL-TRUNC was detected in the lysate, 
almost nothing in the medium and the highest content of CEL-TRUNC was observed in the 







Figure 5.13 The impact of CEL insertion variants on protein secretion and aggregation compared to CEL-WT and 
CEL-TRUNC. HEK293 cells were transiently transfected with different variants of CEL: CEL-WT, CEL-INS9, CEL-INS11 
and CEL-TRUNC. Post-transfection, medium, lysate and pellet fractions were collected and analyzed by SDS-PAGE and 
western blot. A) Three western blots, representing three individual experiments. GAPDH was used as loading control. The 
chemiluminescence exposure was 10 seconds for all blots. B) Quantification of the intensity of each band in the three 
individual western blot experiments. The intensity of the CEL bands was adjusted to GAPDH and normalized towards the 
CEL-WT. The data represents the mean of the normalized values and the error bars are standard error of the mean (SEM) of 
three individual experiments. 
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6. Discussion  
Diseases that are associated with carboxyl ester lipase (CEL) are mainly related to alterations 
occurring in the variable number of tandem repeat (VNTR) region. Disease progression in 
HIV-1 has been linked to variations in VNTR length (Stax et al., 2012), a longer VNTR has 
been associated with alcoholic liver cirrhosis (Fjeld et al., 2016) a CEL-deletion variant 
(CEL-HYB) gives an increased risk for developing chronic pancreatitis (Fjeld et al., 2015). 
The strongest association is seen for MODY8, a syndrome of diabetes and exocrine 
dysfunction. The syndrome is caused by a single base pair deletion in the CEL VNTR region 
and results in a somewhat shorter protein with a completely changed C-terminal due to an 
altered reading frame and a premature stop codon (Ræder et al., 2006). 
One base-pair insertions in the CEL VNTR are quite common, the combined allele frequency 
in normal controls of Northern European descent is around 0.07 (Ræder et al., 2006). Such 
insertions also result in a premature stop codon and a truncated protein. However, compared 
to the MODY8-causing deletion, the stop-codon arises in the same repeat where the insertion 
occurred. Thus, an insertion will lead to a short downstream segment and a truncated protein 
whereas a deletion causes a long and new protein sequence which easily aggregates (Ræder et 
al., 2006, Johansson et al., 2011, Xiao et al., 2016). Insertions in the VNTR have been 
suggested to associate with an increased risk of exocrine dysfunction in diabetes patients 
(Ræder et al., 2006) and with pancreatic cancer (Martinez et al., 2016), but their functional 
properties have not been studied. 
In this project, we aimed to know more about the CEL VNTR insertions variants both at the 
DNA and protein level. We genotyped the VNTR region in pancreatic cancer patients and 
analyzed the localization and frequency of CEL insertions. Tail-specific antibodies for CEL-
WT and CEL insertion variants were tested for western blotting, immunocytochemistry and 
immunohistochemistry. Moreover, the effect of CEL VNTR insertions on protein secretion 





6.1 Insertions in CEL VNTR repeat 9 are linked to a VNTR 
length of 13 
Initially, we searched for insertion variants in the CEL gene in a small material of pancreatic 
cancer patients. We wanted to determine the location of the insertions within the VNTR and 
their frequency. We screened 50 samples and found five cases with insertion in repeat 9, one 
case with insertion in repeat 10 and one case with insertion in repeat 12. Furthermore, from 
our initial screening (Table 5.1), we observed that all five cases with insertions in repeat 9 had 
a VNTR length of 13 repeats on one allele. This could indicate that insertion in repeat 9 is 
linked to the 13-repeat allele.  
To investigate this possible association further, we sequenced the CEL VNTR of all 
remaining samples in the Pancreas Biobank with a VNTR length of 13 repeats (N=25). Of 
these new cases, 18 had an insertion in repeat 9. In total, including INS9 cases from Table 5.1, 
23 of 31 cases with a 13 repeat VNTR length had insertion in repeat 9 (Table 5.2). For 
samples that were heterozygous for a VNTR length of 13 (e.g. 13/16), we did not know 
whether the insertion was located on the allele with 13 repeats or on the other allele. 
However, three of the 31 samples with a VNTR length of 13 were homozygous (13/13) and 
all of them were also homozygous for the insertion in repeat 9.  
Taken together, our findings strongly suggest the one-base pair insertion in the CEL VNTR 
repeat 9 is located on an allele with 13 repeats. Nevertheless, we observed that not all cases 
with the 13 repeat allele had INS9. To decide if the observed correlation between VNTR-









6.2 Is the SNP rs488087 linked to pancreatic ductal 
adenocarcinoma? 
In a previous study, the variant rs488087 was suggested to result in an increased risk for 
developing pancreatic ductal adenocarcinoma (PDAC) (Martinez et al., 2015). However, that 
study used a patient cohort of only 30 patients, which is far too small to make such a 
suggestion. The same argument can be used for the current study: 50 cases is not a large 
enough patient cohort to conclude that any SNP is associated with an increased risk for 
developing PDAC. In addition, a control cohort is needed to see how common this SNP is in 
the normal population compared to patients with PDAC. However, according to the SNP 
database from NCBI, [https://www.ncbi.nlm.nih.gov/snp/] the allele frequency in Europe for 
SNP rs488087 is 0.69 for the C-allele and 0.31 for the T-allele. These are exactly the same 
allele frequencies found in our study. Thus, from the current data, we obtained no indication 
that rs488087 is associated with pancreatic cancer risk in the European population.  
6.3 The specificity of the tail-specific antibodies 
A CEL-WT sequence has a C-terminal that ends with the amino acid sequence PAVIRF. If an 
insertion occurs in the VNTR, it will result in a premature stop codon, a truncated protein and 
a C-terminal sequence that ends with PRAAHG. In a recent study, the authors produced 
antibodies that were specifically directed to these two C-terminal ends, PAVIRF and 
PRAAHG and used them for Western blotting, immunocytochemistry and 
immunohistochemistry (Martinez et al., 2016).  
When we used the same antibodies for western blotting (Fig. 5.7), the tail-specific antibodies 
were highly specific and corresponded to the results published by Martinez and co-workers 
(Martinez et al., 2016). Surprisingly, however, when performing immunofluorescence 
staining on transiently transfected HEK293 cells, the CEL-WT tail-specific antibody (anti-
PAVIRF) exhibited reactivity also towards the insertion variants and CEL-TRUNC (Fig. 
5.9a). In the (Martinez et al., 2016) study, unspecific binding was not observed for the anti-
PAVIRF antibody by immunocytochemistry. One possible reason could be that we use 
different protocols. Further, it should be noted that by immunocytochemistry the proteins are 
detected in a more native form compared to western blot analysis where the proteins are 




Interestingly, when performing immunohistochemistry on PDAC sections (Fig. 5.11) we 
observed that one individual without a CEL VNTR insertion variant in the germline had small 
areas with reactivity towards the anti-PRAAHG antibody. Martinez et al. reported the same 
for eight patients with PDAC, further, they hypothesized that insertions in the VNTR region 
of CEL could be associated with pancreatic cancer and appear as somatic mutations in early 
development of PDAC (Martinez et al., 2016). Since analysis of the anti-PRAAHG antibody 
on pancreatic tissues without cancer was left out of their study we decided to test it on 
pancreatic tissues from four relatively young patients without PDAC (but with other 
pancreatic disease). We observed small anti-PRAAHG positive areas or single cells also in 
normal pancreatic tissue - as in the PDAC case without insertion in the germline (Fig. 5.11 
and 5.12). This may indicate that insertions occur also as somatic mutations in individuals 
without PDAC. However, unspecific anti-PRAAHG antibody binding cannot be ruled out. 
6.4 Is the insertion mutations pathogenic? 
Two clearly pathogenic variants of CEL have been reported: CEL-MODY and CEL-HYB 
(Ræder et al., 2006, Fjeld et al., 2015). CEL-MODY is caused by a single base pair deletion 
which causes an altered reading frame that results in a protein that very easily forms 
intracellular and extracellular aggregates (Johansson et al., 2011). CEL-HYB has three VNTR 
repeats originating from its neighboring pseudogene. When CEL-HYB was expressed in a 
cellular model system, proteins tend to accumulate inside the cell to a much higher degree 
than the normal protein. In addition, CEL-HYB showed impaired secretion (Fjeld et al., 
2015).  
In this study, we wanted to investigate the possible pathogenic effects of CEL insertion 
variants. By cellular fractionation of HEK293 cells we observed that the insertion variants 
were similarly detected in the cell lysate and the medium as the CEL-WT protein (Fig. 13b). 
Interestingly, we observed somewhat more CEL-INS9 than CEL-INS11 in the pellet fraction. 
Since CEL-INS9 has a shorter C-terminal than INS11, the ability to form insoluble protein 
aggregates may increase with shorter VNTR-lengths. To support this, almost nothing of the 
CEL-TRUNC protein was secreted, and instead this variant was highly abundant in the pellet 
fraction. Also, from previous studies on the known pathogenic CEL variants, both amino acid 
composition and length of the C-terminal tail have shown to be crucial for the cellular 




Here, we used HEK293 cells. An advantage is that they are secretory cells from a human 
origin and do not express CEL endogenously (which otherwise may have disturbed the 
interpretation of our results). However, the HEK293 cells are human embryonic kidney cells, 
and may not give a correct image of how insertion variants of CEL behave in their natural 
environment. Thus, it would be more representative to use acinar cells. Two acinar cell lines 
are commercially available: rat acinar cell (ARJ42J) and mouse acinar cells (266-6). 
However, these cell lines are difficult to culture and are biologically different from human 
acinar cells. Unfortunately, no human cell line is available to date.   
Based on our cellular studies, insertions may have an effect of the cellular properties of the 
protein. In addition, we observed that the carrier frequency of CEL insertions in a Norwegian 
pancreas biobank (N=50) was 14 %. However, due to the high carrier frequency of insertions 
in the general population (about 16 %; (Ræder et al., 2006) and the fact that we detected 
possible somatic CEL insertions in patients without PDAC, we cannot confirm that CEL 
insertions are associated with pancreatic cancer. Thus, it is yet not possible to use CEL 
insertions as an early detection tool for PDAC, as suggested by Martinez et al (Martinez et al., 
2016) However, our study is based on CEL insertions in VNTR repeat 9, 10 and 12. 
Investigations of insertion in other VNTR alleles are also needed to completely rule of any 












The overall aim for this study was to understand the biological impact of insertion variants in 
the CEL gene. Based on our findings the following conclusions can be drawn: 
 We have established a strategy for how to analyze CEL insertion variants both at the 
DNA and protein level 
 In samples from a Norwegian pancreas biobank, insertions in CEL VNTR repeat 9 are 
associated with a VNTR length of 13  
 There is no indication that the CEL SNP rs488087 is associated with pancreatic cancer 
risk in the European population 
 CEL insertion variants cannot yet be used as biomarkers to detect somatic mutations in 
pancreatic cancer 
 Compared to normal CEL, proteins with an insertion in VNTR repeat 9 or 11 may 
have a higher tendency to accumulate in the insoluble pellet fraction when expressed 











8. Future perspectives  
The VNTR region is a critical region which should be further investigated to gain a better 
understanding of how CEL is involved in pancreatic disease. To analyze CEL VNTR 
insertions in more depth, one should focus on the following studies:  
 Analyze larger patient and control cohort -  to further study insertions in the VNTR 
region and to investigate if insertions could be located in other repeats than 9, 10 and 
12 
 Sequence DNA from the patients without PDAC that displayed reactivity to anti-
PRAAHG to observe if the insertions were germline or somatic  
 Test the tail-specific antibodies in protein extracts from pancreatic juice isolated from 
patients with and without insertions in the germline  
 Study the effect of a CEL variant with an insertion in a repeat number lower than 9, to 
investigate if this would have stronger impact on protein properties than what 
observed for INS9 
 Transfect CEL insertion variants into acinar cells to analyze them in a more 
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Appendix 1. Binding sites for primers used in the Long-range PCR to amplify CEL exon 8-11. L11F is the forward primer 







Appendix 2. Binding sites for primers used to sequence CEL exon 11. EF is the forward primer (marked in green) and 
VNTR-R is the reverse primer (marked in green). The VNTR region in exon 11 is marked in bold letters. 
 
